# Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

> **NCT03175835** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Rosuvastatin 20 mg
- **DRUG:** CKD-519 200 mg
- **DRUG:** Rosuvastatin 20 mg & CKD-519 200 mg

## Key facts

- **NCT ID:** NCT03175835
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-08
- **Primary completion:** 2017-06-19
- **Final completion:** 2017-06-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175835, "Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03175835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*